Global Polycystic Kidney Disease Market - 2023-2030

Global Polycystic Kidney Disease Market - 2023-2030

Global Polycystic Kidney Disease Market reached US$ 495 million in 2022 and is expected to reach US$ 769 million by 2030 growing with a CAGR of 5.8% during the forecast period 2023-2030.

Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the development and continued growth of numerous fluid-filled kidney cysts, resulting in ultimate kidney function loss in most individuals. ADPKD manifestations are not limited to the kidney. It is well established that arterial stiffness, a significant predictor of future cardiovascular events and mortality, is present early in ADPKD.

In people with polycystic kidney disease, the kidneys become enlarged with cysts that impair normal kidney function. This can sometimes lead to kidney failure and the need for dialysis or kidney transplantation. In US, it is the fourth leading cause of kidney failure. Men and women are equally at risk for the disease. It causes about 5% of all kidney failure.

Furthermore, Increasing research funding is a critical polycystic kidney disease trend propelling the market growth. The polycystic kidney disease market is driven by the number of emerging markets and research and development activities raising investment for developing advanced technologies and surging drug approvals and launches.

Dynamics

Rising Advancements

Recent approaches to identifying novel predictive biomarkers have ranged from assessing disease severity based on the urine concentrating ability in patients. Furthermore, tolvaptan-treated individuals with a more significant percentage increase in copeptin from baseline to week 3 had a better disease outcome, with less kidney growth and eGFR decline after three years. 30 Other biomarkers that have shown potential as prognostic indicators of disease progression are kidney injury molecule 1, β2 microglobulin, neutrophil gelatinase-associated lipocalin, monocyte chemoattractant protein 1, fibroblast growth factor 23, and microRNAs, among others.

The University of Colorado and the University of Maryland collaborated to conduct phase 2 clinical trials to determine the safety and tolerability of empagliflozin in ADPKD patients. Height-adjusted total kidney volume will be examined by magnetic resonance imaging at baseline, three months, and 12 months after treatment with empagliflozin. The estimated completion date is July 1, 2025.

Initiatives To Raise Awareness

Initiatives to raise awareness about polycystic kidney disease are also one of the factors that is expected to drive the market share. Polycystic kidney disease management strategies, as well as key firms active in the manufacturing and developing enhanced pharmaceuticals for effective polycystic kidney disease therapy, are drivers driving the growth of the polycystic kidney disease market.

The PKD Foundation Centers of Excellence and Partner Clinics is a national network of providers meeting patient-centered, specialized ADPKD criteria established by the PKD Foundation. This elite designation for nephrology practices and clinics helps those affected by ADPKD better manage their disease, maintain and improve their quality of life, and plan for the future. For instance, the Polycystic Kidney Disease Foundation is the only non-profit organization in the United States dedicated only to treating and curing polycystic kidney disease. Over 1,300 research investigations have been financed, with USD 1.5 billion in research money leveraged.

High Cost of the Treatment

The cost of managing polycystic kidney disease is high, which is expected to hinder market growth. For instance, in sensitivity assessments, the anticipated total annual prices ascribed to ADPKD ranged from $10.3 to $15.6 billion.

Direct healthcare expenditures accounted for $5.7 billion (78.6%) of the total $7.3 billion costs in the basic scenario, with patients requiring renal replacement treatment accounting for the majority ($3.2 billion; 43.3%).

Indirect expenses accounted for $1.4 billion (19.7%), with productivity loss owing to unemployment ($784 million; 10.7%) and lower productivity at work ($390 million; 5.3%) accounting for the majority of the cost. This issue may further impede the expansion of the global polycystic kidney disease market.

Segment Analysis

The global polycystic kidney disease market is segmented based on type, treatment type, end user and region.

The Autosomal Dominant Polycystic Kidney Disease (ADPKD) Segment Accounted for Approximately 47.5% of the Market Share

Autosomal dominant polycystic kidney disease, or ADPKD, is a form of chronic kidney disease caused by mutations in the PKD1 or PKD2 genes. ADPKD is the fourth leading cause of chronic kidney disease (CKD), affecting 1 in every 400 to 1,000 people (approximately 140,000 patients in the US), and is the most common kidney disorder passed down through family members. More than 50% of ADPKD patients develop renal failure by age 50, followed by dialysis and kidney transplantation.

In March 2023, POXEL SA, a clinical-stage biopharmaceutical company developing innovative treatments for chronic severe diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, launched the publication of preclinical results in autosomal dominant polycystic kidney disease (ADPKD) for PXL770, a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator. It is focused on treating adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). The potential utility of AMPK activation is confirmed for this disease and supports the development of PXL770 in a Phase 2 clinical program for ADPKD.

Geographical Analysis

North America accounted for Approximately 39.5% of the Market Share in 2022

North America is leading in the drug discovery pipeline as the demand is more in that region due to rise in the chronic diseases. According to the Centers for Disease Control and Prevention (CDC), chronic diseases are the leading cause of death and disability in the United States. About 133 million Americans, i.e., 45% of the population, have at least one chronic disease. Chronic diseases are responsible for seven out of every 10 deaths in the U.S., killing more than 1.7 million Americans every year. Hence, drug development became mandatory for the treatment of various diseases in this region.

Major drug developers are investigating their lead agents in making different drugs gradually progress into the front line of polycystic kidney disease treatment. Pipeline therapies such as Empagliflozin, Bardoxolone methyl, Ziltivekimab, KBP-5074, AZD9977, and others are under different phases of clinical trials.

For instance, in January 2023, the U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets, which is being investigated as a potential treatment to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD), Boehringer Ingelheim and Eli Lilly and Company announced.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global polycystic kidney disease market, as countries grappled with lockdowns, supply chain disruptions, and reduced economic activity.

The polycystic kidney disease (PKD) market faced challenges because of a shortage of highly qualified workers and a lack of healthcare infrastructure in developing nations. Lack of knowledge and COVID-19's impact on the supply chain will constrain and impede the market's expansion. There is an urgent need to improve the transparency of the overall pharmaceutical information. During the pandemic, people living with cancer, heart diseases, chronic respiratory diseases, diabetes, and other NCDs experienced difficulties in accessing their routine medicines. Hence, the market is expected to be impacted during covid 19 pandemic.

By Type
• Autosomal dominant polycystic kidney disease (ADPKD)
• Autosomal recessive polycystic kidney disease (ARPKD)

By Treatment Type
• Diagnosis
Urine Tests
Blood Tests
Imaging Tests
Ultrasound
Computed Tomography
Magnetic Resonance Imaging
Others
• Drug/Therapy
Tolvaptan
fluoxetine
venlafaxine
duloxetine
Dialysis
Kidney Transplantation
Others

By End User
• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• In April 2023, XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the grant of Orphan Drug Designation for oxypurinol, orphan-drug designation request of oxypurinol is granted for the treatment of autosomal dominant polycystic kidney disease.
• In November 2022, Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, announced the dosing of the first patient in the Phase 1b MAD study of RGSL8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).
• In March 2023, POXEL SA, a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including launched the publication of preclinical results in autosomal dominant polycystic kidney disease (ADPKD) for PXL770, a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator.

Competitive Landscape

The major global polycystic kidney disease market players in the market include Otsuka Pharmaceuticals, Camber Pharmaceuticals, Apotex Corp, Ascend Laboratories, Par Pharmaceuticals, Teva Pharmaceutical Industries, Merck and Co, Accord Healthcare, Pfizer, and PD-Rx Pharmaceuticals, Inc among others.

Why Purchase the Report?
• To visualize the global polycystic kidney disease segmentation based on type, treatment type, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of polycystic kidney disease market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global polycystic kidney disease market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies